ArticleNeuro-oncology advances

Days gained response discriminates treatment response in patients with recurrent glioblastoma receiving bevacizumab-based therapies.

Kyle W Singleton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.